BioCentury
ARTICLE | Clinical News

Clonidine: Completed Phase III enrollment

July 21, 2014 7:00 AM UTC

BioDelivery Sciences completed enrollment of 140 patients with functional skin nociceptors in the double-blind, placebo-controlled, U.S. Phase III RHAPSODY trial evaluating clonidine topical gel for 12 weeks. The company expects to complete an interim analysis from 50% of patients this quarter, with top-line data slated for year end. BioDelivery Sciences said it also began rolling over patients from the trial into a 12-month, long-term safety study and expects to begin a second Phase III trial in 1Q15. ...